FIG 3.

The effects of HMT inhibitor specific to EZH2 on restoration of CDKN2A/B induction by TGFβ in RMS cells. (A) Representative Western blots for the indicated proteins using lysate from RD cells incubated with or without HMT inhibitors for 7 days. (B) Quantitative analysis of Smad7 mRNA expression in tested RMS cell lines preincubated with DZNep following with TGFβ induction. (C) Quantitative analysis of mRNA expression of the indicated genes in RD and JR cells preincubated with EPZ-6438 following with TGFβ induction. For quantitative mRNA expression in panels B and C, gene expression of the indicated genes are presented as fold change over expression in vehicle treated cells. (D) Quantitative analysis of EZH2 expression following targeted shRNA knockdown through qRT-PCR (top) and Western blotting (bottom) in RD cells. (E) Quantitative analysis of mRNA expression of the indicated genes with RD cells stably expressing either shRNA control or shRNA targeting EZH2, followed by vehicle or TGFβ treatment for 72 h. V, Vehicle; T, TGFβ. Error bars: ±SEM. ^¶P < 0.05, “HMT inhibitor” vs. “control”; *P < 0.05, Control vs EZH2 shRNA; ^§P < 0.05, T vs. V.